Eplerenone, a new mineralocorticoid antagonist: In vitro and in vivo studies

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 3, 2000, Pages 138-142

  Funder, John W ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE; OXPRENOATE POTASSIUM; SODIUM CHLORIDE; SPIRONOLACTONE;

ADRENAL GLAND; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG STRUCTURE; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

EID: 0034087499     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200006000-00006     Document Type: Review

References (30)

1. 1 Blair-West JR, Coghlan JP, Cran E, Denton DA, Funder JW, Scoggins BA: Increased aldosterone secretion during sodium depletion with inhibition of renin release. Am J Physiol 1973, 224:1409-1414.
2. 2 Okubo S, Niimura F, Nishimura H, Takemoto F, Fogo A, Matsusaka T, Ichikawa I: Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997, 99:855-860.
3. 3 Crabbe J: Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro. J Clin Invest 1961, 40:2103-2110.
4. 4 Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C: ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 1990m 258:E649-653.
5. 5 Gomez-Sanchez EP, Fort C, Thwaites D: Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rates. Am J Physiol 1992, 262:E96-99.
6. 6 Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
7. 7 Young M, Head G, Funer J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269:E657-662.
8. 8 Pitt B, Zannas F, Remme WJ, Cody R, Castaigne A, Perez A, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999, 341:709-717. Overwhelming evidence for a cardioprotective role of aldosterone antagonists in congestive cardiac failure, and by inference of aldosterone in its pathophysiology.
9. 9 Krozowski ZS, Funder JW: Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983, 80:6056-6060.
10. 10 Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, et al.: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
11. 11 Funder JW, Pearce P, Smith R, Smith AI: Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
12. 12 Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, et al.: Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986-989.
13. 13 Wilson RC, Krozowski ZS, Li K, Obeyesekere V, Razzaghy-Azar M, Harbison MD, et al.: A mutation in the HSD11B2 gene in a family with Apparent Mineralocorticoid Excess. J Clin Endocrinol Metab 1995, 80:2263-2266.
14. 14 Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR: Mineralocorticosteroid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 2:821-824.
15. 15 Funder JW, Pearce PT, Myles K, Roy LP: Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte excretion: toward a redefinition of mineralocorticoid action. FASEB J 1990, 4:3234-3238.
16. 16 Chen S, Bhargava A, Mastroberardino L, Meijer O, Wang J, Buse P, et al.: Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci 1999, 96:2514-2519. First demonstration after > 30 years of attempts in various laboratories of an aldosterone-induced protein.
17. 17 Lombes M, Alfraidy N, Eugene E, Lessana A, Farman N. Bonvalet JP: Prerequisite for aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in human heart. Circulation 1995, 95:175-182.
18. 18 Sato A, Suzuki Y, Saruta T: Effects of spironolactone and angiotensin-converting enzyme inhibitor in left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999, 22:17-22.
19. 19 Napoli C, Di Gregorio F, Leccese M, Abete P, Ambrosio G, Giusti R, et al.: Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: the Cross-Sectional Primary Aldosteronism and Heart Italian Multicenter Study. J Invest Med 1999, 47:212-221.
20. 20 de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al.: Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, m240:650-656.
21. 21 Funder JW, Myles K, Delyani J, Ward M, Kanellakis P, Bobik A: Eplerenone, a selective aldosterone receptor antagonist: in vitro and in vivo studies. 25th International Aldosterone Conference 1999:23. First report of effect of eplerenone in preventing restenosis in experimental angioplasty in pigs.
22. 22 de Gasparo M, Whitebread SE, Preiswek G, Jeunemaitre X, Corbol P, Menard J: Antialdosterones: incidence and prevention of sexual side effects. J Ster Biochem 1989, 32:223-227.
23. 23 Delyani J, Myles K, Funder J: Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens 1998, 11:94A. First report of differential plasma binding of eplerenone and spironolactone.
24. 24 Frierdich G, Schuh J, Brown M, Nochowiak D, Blehm D, Delyani JA: Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis. Am J Hypertens 1998, 11:94A. Extension of previous studies from various laboratories on the ability of MR antagonists (sprionolactone, potassium canrenoate) to block cardiac/CNS effects of aldosterone.
25. 25 Rocha R, Stier CT, Adler GK, Kifor I, Mullen D, Williams GH: Selective aldosterone antagonist or adrenalectomy prevents L-NAMF. Ang II-induced renal injury in rats. Am J Hypertens 1999, 12:15A.
26. 26 Rocha R, Praveen N, Chander PN, Khanna K, Zuckerman A, Stier CT: Mineralocorticoid blockade reduces casular injury in stroke-prone hypertensive rate. Hypertension 1998, 451-458. At a dose that does not reduce blood pressure, spironolactone completely protected against stroke in stroke-prone spontaeously hypertensive rats.
27. 27 Roniker B: Eplerenone, a selective antagonist of the aldosterone receptor. Hypertension 1997, 30:995.
28. 28 Epstein M, Alexander JC, Roniker B: Eplerenone, a new selective aldosterone receptor antagonist (SARA): efficacy in patients with mild to moderate hypertension. J Am Soc Nephrol 1998, 9:A1640.
29. 29 Pitt B, Roniker B: Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose finding study with heart failure. J Am Coll Cardiol 1999, 33:188A.
30. 30 Rabasseda X, Silvestre J, Castaner J: Eplerenone: Antihypertensive, treatment of heart failure, aldosteone antagonist. Drugs Future 1999, 24:488-501. An excellent summary of the synthesis, pharmacologic actions, and clinical studies on Eplerenone.